Autopsy report · NCT00860093

Efficacy and Safety of Using MPC-5971 in Subjects Undergoing Shock Wave Lithotripsy

“Sponsor Corporate Business Decision”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 1 month before it started.
• Ran for about 8 months before it stopped.
• 135 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Mission Pharmacal

Sponsor type

Industry

Conditions

Nephrolithiasis

Interventions

placebo; MPC-5971

Participants

135

Sites

3

Countries

United States

Trials that died the same way

• A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
  “Sponsor business decision” (91% match in meaning)
• Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
  “business decision by sponsor” (88% match in meaning)
• Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
  “Sponsor's business decision” (87% match in meaning)
• A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
  “Sponsor's strategic business decision” (85% match in meaning)
• Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors
  “Sponsor strategic business decision” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.